Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837413 | 0.88 | — | — | |
| SCHEMBL16312486 | 0.88 | CYP2D6 (0.41) | CYP2D6 | |
| SCHEMBL19544290 | 0.84 | DNM1 (0.38) | CYP2D6FDPS | |
| SCHEMBL13900814 | 0.83 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL12516837 | 0.83 | CYP2D6 (0.47) | CYP2D6FDPS | |
| SCHEMBL24375706 | 0.82 | DNM1 (0.42) | FDPS | |
| SCHEMBL936164 | 0.80 | CYP2D6 (0.50) | CYP2D6 | |
| SCHEMBL20610038 | 0.77 | TSHR (0.33) | — | |
| SCHEMBL24747411 | 0.76 | CYP2D6 (0.32) | CYP2D6 | |
| SCHEMBL1956399 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083532-A1 | NOVEL USES | NANYANG POLYTECHNIC (SG) | 2012-04-05 | — | — | US | disclosed |
| WO-2010144059-A2 | NOVEL USES | NANYANG POLYTECHNIC (SG) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144055-A1 | NOVEL COMPOUNDS AND USES THEREOF | NANYANG POLYTECHNIC (SG) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083532-A1 | NOVEL USES | PYCR1, CYP11B2, IL4I1 | CYP2D6 1562/4885FDPS 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.